Compare CORT & HIMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | HIMS |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.8B |
| IPO Year | 2001 | 2019 |
| Metric | CORT | HIMS |
|---|---|---|
| Price | $63.63 | $14.61 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 15 |
| Target Price | ★ $142.60 | $27.92 |
| AVG Volume (30 Days) | 1.2M | ★ 13.1M |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | $761,407,000.00 | ★ $2,347,637,000.00 |
| Revenue This Year | $52.09 | $33.78 |
| Revenue Next Year | $44.73 | $22.88 |
| P/E Ratio | $57.37 | ★ N/A |
| Revenue Growth | 12.79 | ★ 59.00 |
| 52 Week Low | $28.66 | $13.74 |
| 52 Week High | $126.38 | $40.99 |
| Indicator | CORT | HIMS |
|---|---|---|
| Relative Strength Index (RSI) | 20.65 | 25.40 |
| Support Level | $30.24 | $13.74 |
| Resistance Level | $122.93 | $31.17 |
| Average True Range (ATR) | 4.77 | 1.88 |
| MACD | -0.14 | -0.79 |
| Stochastic Oscillator | 1.89 | 1.02 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.